Kintara Therapeutics (FRA:3DMA) EBIT : €-7.84 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics EBIT?

Kintara Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was €-2.22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-7.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kintara Therapeutics's annualized ROC % for the quarter that ended in Jun. 2024 was -1,405.87%. Kintara Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -1,404.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kintara Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -49.14%.

Kintara Therapeutics EBIT Historical Data

The historical data trend for Kintara Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics EBIT Chart

Kintara Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT

Get a 7-Day Free Trial

-7.23

-17.91

-21.46

-13.66

-7.85

Kintara Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
EBIT	Get a 7-Day Free Trial															-3.09	-2.78	-0.93	-1.92	-2.22

Competitive Comparison of Kintara Therapeutics's EBIT

For the Biotechnology subindustry, Kintara Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's EV-to-EBIT falls into.

Kintara Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.84 Mil.

Kintara Therapeutics (FRA:3DMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kintara Therapeutics's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2024 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-8.864 * ( 1 - 0% )	/	( (0.635	+	0.626)	/ 2 )
=	-8.864	/	0.6305
=	-1,405.87 %

where

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.85	-	1.234	-	( 5.843	-	max(0, 1.234	-	6.215	+	5.843	))
=	0.635

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.762	-	2.099	-	( 4.56	-	max(0, 2.099	-	5.136	+	4.56	))
=	0.626

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Kintara Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2024		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-8.864	/	( ( (0.636 + max(-1.053, 0))	+	(0.626 + max(-1.523, 0)) )	/	2 )
=	-8.864	/	( ( 0.636	+	0.626 )	/	2 )
=	-8.864	/	0.631
=	-1,404.75 %

where Working Capital is:

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.181)	-	(1.234	+	0	+	0)
=	-1.053

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.576)	-	(2.099	+	0	+	0)
=	-1.523

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kintara Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-7.843	/	15.962
	=	-49.14 %

Kintara Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (FRA:3DMA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines